Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Clinical guidelines should establish clear timelines, and health care systems should prioritize timely treatment initiation and completion,” researchers concluded.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

Chinese and international oncologists witness the release of a breakthrough finding by a Chinese pharma company during the ...

BeiGene’s Tevimbra (tislelizumab) has been recommended by the European Medicines Agency’s human medicines committee as part of a first-line combination treatment for an aggressive form of lung cancer.

Digital banking provider Tyfone today announced Partners 1st Federal Credit Union (Partners 1st, Fort Wayne, Ind.-based and 45,600 members) selected its nFinia® Digital Banking Platform for consumer ...